Zymeworks INC Form 4 insider transactions

Zymeworks Inc. reports that Hollywood Mark, EVP & Chief Operating Officer, acquired 939 shares of common stock through the company's Employee Stock Purchase Plan on July 6, 2026.

Zymeworks Inc. EVP and General Counsel Paul R. Schneider was granted 178,000 stock options and 119,000 restricted stock units.

Adam Schayowitz, EVP of Research & Development at Zymeworks Inc., reported transactions involving stock options and restricted stock units.

Zymeworks Inc. EVP Scott Platshon filed a Form 4 detailing transactions involving stock options, restricted stock units, and performance stock units.

Kristin Stafford, EVP and CFO of Zymeworks Inc., was granted stock options and restricted stock units on April 6, 2026.

Zymeworks Inc.'s EVP & Chief Operating Officer, Mark Hollywood, reported the vesting of restricted stock units and the acquisition of new stock options and performance stock units, alongside a tax-related stock sale.

Zymeworks Inc. Director Brian N. Cherry was granted 23,000 stock options and 15,400 restricted stock units.

Zymeworks' EVP & Chief Medical Officer, Jeffrey T.L. Smith, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax withholding obligations.

Zymeworks Inc. Director Gregory Austin Ciongoli received grants of 11,500 stock options and 7,700 restricted stock units, vesting in January 2027.

Zymeworks Inc. Director Kelvin Neu was granted 11,500 stock options and 7,700 restricted stock units, vesting in January 2027.

Zymeworks Inc. Director Robert E. Landry received a grant of 11,500 stock options and 7,700 restricted stock units as part of his compensation.

Zymeworks Inc. Director Alessandra Cesano acquired stock options and restricted stock units under a pre-arranged plan.

Zymeworks Inc. Director Carlos Campoy acquired 11,500 stock options and 7,700 restricted stock units, vesting in January 2027.

Zymeworks Inc. director Susan Mahony was granted 11,500 stock options and 7,700 restricted stock units, vesting in January 2027.

Zymeworks' Chief Scientific Officer, Paul Andrew Moore, reported a series of equity transactions including RSU vesting, tax-related stock sales, and new grants of stock options, restricted stock units, and performance stock units.

Zymeworks Inc. CEO Kenneth Galbraith reported significant equity transactions, including RSU vesting, stock option grants, and a non-discretionary 'sell-to-cover' sale.

Zymeworks' EVP, Chief Business & Financial Officer, Leone D. Patterson, acquired 459 shares of common stock through the company's Employee Stock Purchase Plan.

Zymeworks' EVP & Chief Medical Officer, Jeffrey T L Smith, sold 10,538 shares of common stock to cover tax withholding obligations following the vesting of restricted stock units.

Zymeworks Inc. Chair & CEO Kenneth Galbraith reported pre-scheduled vesting of restricted stock units and subsequent tax-related stock sales set for January 5, 2026.

Zymeworks Inc.'s Chief Scientific Officer, Paul Andrew Moore, reported the vesting of restricted stock units and subsequent non-discretionary sales to cover tax obligations.

Zymeworks Inc. Chair & CEO Kenneth Galbraith reported the vesting of 100,000 restricted stock units and a subsequent non-discretionary sale of 47,528 shares to cover tax obligations.

A Zymeworks Inc. director significantly increased their beneficial ownership through direct stock purchases and new stock option grants.

Zymeworks Inc. Director Robert E. Landry was granted 62,000 stock options with an exercise price of $12.44, vesting over 36 months.

EcoR1 Capital, LLC and its affiliates, including director Oleg Nodelman, have significantly increased their beneficial ownership in Zymeworks Inc. by exercising pre-funded warrants.

EcoR1 Capital, along with related entities, has increased its holdings in Zymeworks Inc. through a series of stock purchases.

EcoR1 Capital, a significant shareholder in Zymeworks Inc., has increased its holdings through multiple stock purchases made on April 16 and 17, 2025.

EcoR1 Capital, a significant shareholder in Zymeworks Inc., has increased its holdings through multiple stock purchases in early April 2025.

EcoR1 Capital, a significant shareholder in Zymeworks Inc., has increased its holdings through a series of open market purchases of common stock.

EcoR1 Capital, a significant shareholder in Zymeworks Inc., has increased its holdings through open market purchases of common stock.

EcoR1 Capital, a significant shareholder in Zymeworks Inc., has increased its holdings through a series of open market purchases between March 20-24, 2025.